Xenon Pharmaceuticals (NASDAQ:XENE) Sees Large Volume Increase on Analyst Upgrade

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) saw an uptick in trading volume on Wednesday after Wells Fargo & Company raised their price target on the stock from $49.00 to $68.00. Wells Fargo & Company currently has an overweight rating on the stock. 1,535,168 shares were traded during trading, an increase of 22% from the previous session’s volume of 1,255,933 shares.The stock last traded at $60.2830 and had previously closed at $60.61.

A number of other research analysts have also commented on XENE. Bank of America reiterated a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday. HC Wainwright raised their price objective on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday. Stifel Nicolaus set a $66.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 10th. JPMorgan Chase & Co. upped their target price on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Finally, Chardan Capital raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $71.94.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, insider Christopher John Kenney sold 2,771 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $166,564.81. Following the sale, the insider directly owned 4,729 shares in the company, valued at approximately $284,260.19. This represents a 36.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Ian Mortimer sold 11,269 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total value of $677,379.59. Following the completion of the sale, the chief executive officer owned 14,731 shares in the company, valued at approximately $885,480.41. This represents a 43.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 326,647 shares of company stock valued at $19,066,951. 4.07% of the stock is currently owned by corporate insiders.

Xenon Pharmaceuticals News Roundup

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 trial: azetukalner met its goal in focal‑onset seizures and Xenon said it plans an NDA filing in 3Q‑2026 — a clear clinical milestone that supports future revenue potential. XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
• Positive Sentiment: Multiple analyst upgrades and higher price targets (Wells Fargo, Wedbush, HC Wainwright, Deutsche Bank and others) increased street conviction and pushed consensus targets materially above prior levels. That analyst momentum typically supports share appreciation. Deutsche Bank Raises XENE Price Target
• Positive Sentiment: Independent analyst commentary (Needham) expects further upside, reinforcing the buy‑side narrative around azetukalner’s market opportunity. Xenon Pharmaceuticals Stock Price Expected to Rise, Needham & Company LLC Analyst Says
• Neutral Sentiment: Earlier reports noted a proposed $500M offering; that story evolved as management and bankers adjusted size and pricing in response to demand and market conditions. The initial notice itself was informational. Xenon Pharmaceuticals announces proposed $500M public share offering
• Negative Sentiment: Upsized public offering priced at $57.00 per share to raise ~ $650M (with a 30‑day option for additional shares). While the cash strengthens the balance sheet and funds registrational/launch activities, the scale of the sale increases near‑term dilution and likely pressured the stock despite positive trial and analyst news. Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Elevation Point Wealth Partners LLC acquired a new position in Xenon Pharmaceuticals in the second quarter valued at about $32,000. Danske Bank A S acquired a new stake in shares of Xenon Pharmaceuticals during the third quarter worth approximately $32,000. Blue Trust Inc. increased its holdings in shares of Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 717 shares in the last quarter. Kestra Advisory Services LLC bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $33,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Xenon Pharmaceuticals in the 3rd quarter worth approximately $39,000. 95.45% of the stock is owned by institutional investors.

Xenon Pharmaceuticals Trading Down 2.6%

The firm has a market capitalization of $4.91 billion, a price-to-earnings ratio of -13.54 and a beta of 0.91. The firm has a fifty day moving average price of $43.23 and a 200 day moving average price of $41.69.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the previous year, the business earned ($0.84) earnings per share. As a group, equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.